June 20, 2018 / 11:46 AM / 6 months ago

BRIEF-TG Therapeutics, Novimmune Announce Global Agreement For Development And Commercialization Of Anti-CD47/ Anti-CD19 bispecific antibody

June 20 (Reuters) - Novimmune SA IPO-NOVI.S:

* TG THERAPEUTICS AND NOVIMMUNE SA ANNOUNCE GLOBAL AGREEMENT FOR DEVELOPMENT AND COMMERCIALIZATION OF A NOVEL ANTI-CD47/ ANTI-CD19 BISPECIFIC ANTIBODY

* TG THERAPEUTICS INC - COMPANIES WILL JOINTLY DEVELOP PRODUCT ON A WORLDWIDE BASIS, FOCUSING ON INDICATIONS IN AREA OF HEMATOLOGIC B-CELL MALIGNANCIES

* TG THERAPEUTICS - CLINICAL TRIALS ON TG-1801 ARE EXPECTED TO COMMENCE LATER THIS YEAR OR EARLY IN 2019

* TG THERAPEUTICS - TO MAKE UP-FRONT & MILESTONES PAYMENTS BASED ON EARLY CLINICAL DEVELOPMENT

* TG THERAPEUTICS - TO BE RESPONSIBLE FOR COSTS OF CLINICAL DEVELOPMENT OF PRODUCTS THROUGH END OF PHASE II Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below